Navigation Links
OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- OncoSec Medical, Inc. (OTC Bulletin Board: ONCSD) announced today that Mr. Punit Dhillon, President and CEO, will present a company overview on Wednesday, March 16 at 2:00 pm PT at the ROTH 23rd Annual Growth Stock Conference being held at the Ritz-Carlton, Laguna Niguel, CA.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Conference details: http://www.roth.com/main/Page.aspx?PageID=7236

About OncoSec Medical Inc.

OncoSec (OTC BB: ONCS.D), based in San Diego, California, designs, develops and commercializes innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs or where currently approved therapies are inadequate based on their efficacy level or side effect profile. The company's therapies are based on the use of electroporation delivery in combination with an approved chemotherapeutic drug or a cytokine agent to treat solid tumors. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine
4. Reportlinker Adds Medical Devices Market in Europe 2008-2012
5. R. Lindholm Named to Crux Biomedical Board
6. Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call
7. Dehaier Medical Systems Signs New Distribution Agreement to Distribute eVent Medical Ventilators
8. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
9. Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System
10. BridgePoint Medical Closes $9.1 Million Series C Financing
11. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... research provides evidence that an old drug may provide relief ... today that will be presented at the American Academy ... , April 22 to 28, 2017. ... oral drug levodopa has long been considered the gold standard, ... progresses, the effects of the medication can partially wear off ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® ... ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy ... cost savings as well as more stable pricing over time. Now it’s even ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... an agreement to be the preferred physical therapy provider for Derby City CrossFit, ... to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical ...
Breaking Medicine News(10 mins):